表紙
市場調査レポート

ニコチン中毒症:パイプライン製品の分析

Nicotine Addiction - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 245978
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
ニコチン中毒症:パイプライン製品の分析 Nicotine Addiction - Pipeline Review, H2 2016
出版日: 2016年08月17日 ページ情報: 英文 64 Pages
概要

ニコチン中毒症は、ニコチンへの薬物依存によって引き起こされるタバコ製品への依存症です。年齢、抑うつ傾向、統合失調症、PTSD、アルコール依存などの要因によって発病し、摂取中止の際には手の震え、発汗、神経過敏、心拍数の上昇などといった離脱症状がでる場合もあります。ニコチン置換療法などにより治療を行います。

当レポートでは、ニコチン中毒症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

ニコチン中毒症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

ニコチン中毒症:企業で開発中の治療薬

ニコチン中毒症:大学/機関で研究中の治療薬

ニコチン中毒症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

ニコチン中毒症:企業で開発中の製品

ニコチン中毒症:大学/機関で研究中の製品

ニコチン中毒症の治療薬開発に従事している企業

  • Addex Therapeutics Ltd
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Embera NeuroTherapeutics, Inc.
  • Hager Biosciences, LLC
  • Heptares Therapeutics Limited
  • Omeros Corporation
  • RTI International

ニコチン中毒症:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

ニコチン中毒症:最近のパイプライン動向

ニコチン中毒症:休止中のプロジェクト

ニコチン中毒症:開発が中止された製品

ニコチン中毒症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8366IDB

Summary

Global Markets Direct's, 'Nicotine Addiction - Pipeline Review, H2 2016', provides an overview of the Nicotine Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction
  • The report reviews pipeline therapeutics for Nicotine Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Nicotine Addiction therapeutics and enlists all their major and minor projects
  • The report assesses Nicotine Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Nicotine Addiction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Nicotine Addiction Overview 7
  • Therapeutics Development 8
  • Pipeline Products for Nicotine Addiction - Overview 8
  • Pipeline Products for Nicotine Addiction - Comparative Analysis 9
  • Nicotine Addiction - Therapeutics under Development by Companies 10
  • Nicotine Addiction - Therapeutics under Investigation by Universities/Institutes 11
  • Nicotine Addiction - Pipeline Products Glance 12
  • Clinical Stage Products 12
  • Early Stage Products 13
  • Nicotine Addiction - Products under Development by Companies 14
  • Nicotine Addiction - Products under Investigation by Universities/Institutes 15
  • Nicotine Addiction - Companies Involved in Therapeutics Development 16
  • Addex Therapeutics Ltd 16
  • Astraea Therapeutics, LLC 17
  • Cerecor Inc. 18
  • Chronos Therapeutics Limited 19
  • Embera NeuroTherapeutics, Inc. 20
  • Hager Biosciences, LLC 21
  • Heptares Therapeutics Limited 22
  • Omeros Corporation 23
  • Nicotine Addiction - Therapeutics Assessment 24
  • Assessment by Monotherapy Products 24
  • Assessment by Combination Products 25
  • Assessment by Target 26
  • Assessment by Mechanism of Action 28
  • Assessment by Route of Administration 30
  • Assessment by Molecule Type 31
  • Drug Profiles 33
  • (metyrapone + oxazepam) - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • ADX-71441 - Drug Profile 35
  • Product Description 35
  • Mechanism Of Action 35
  • R&D Progress 35
  • AT-1001 - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • CERC-501 - Drug Profile 40
  • Product Description 40
  • Mechanism Of Action 40
  • R&D Progress 40
  • EORA-101 - Drug Profile 42
  • Product Description 42
  • Mechanism Of Action 42
  • R&D Progress 42
  • OMS-405 - Drug Profile 43
  • Product Description 43
  • Mechanism Of Action 43
  • R&D Progress 43
  • OMS-527 - Drug Profile 44
  • Product Description 44
  • Mechanism Of Action 44
  • R&D Progress 44
  • Small Molecule for Nicotine Addiction - Drug Profile 46
  • Product Description 46
  • Mechanism Of Action 46
  • R&D Progress 46
  • Small Molecule for Psychiatric Disorders - Drug Profile 47
  • Product Description 47
  • Mechanism Of Action 47
  • R&D Progress 47
  • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 48
  • Product Description 48
  • Mechanism Of Action 48
  • R&D Progress 48
  • Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile 49
  • Product Description 49
  • Mechanism Of Action 49
  • R&D Progress 49
  • Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile 50
  • Product Description 50
  • Mechanism Of Action 50
  • R&D Progress 50
  • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 51
  • Product Description 51
  • Mechanism Of Action 51
  • R&D Progress 51
  • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 52
  • Product Description 52
  • Mechanism Of Action 52
  • R&D Progress 52
  • URB-694 - Drug Profile 53
  • Product Description 53
  • Mechanism Of Action 53
  • R&D Progress 53
  • Vaccine for Nicotine Addiction - Drug Profile 54
  • Product Description 54
  • Mechanism Of Action 54
  • R&D Progress 54
  • Vaccine for Nicotine Addiction - Drug Profile 55
  • Product Description 55
  • Mechanism Of Action 55
  • R&D Progress 55
  • Vaccine for Nicotine Addiction - Drug Profile 56
  • Product Description 56
  • Mechanism Of Action 56
  • R&D Progress 56
  • Vaccine for Nicotine Addiction - Drug Profile 57
  • Product Description 57
  • Mechanism Of Action 57
  • R&D Progress 57
  • Nicotine Addiction - Dormant Projects 58
  • Nicotine Addiction - Discontinued Products 59
  • Nicotine Addiction - Product Development Milestones 60
  • Featured News & Press Releases 60
  • Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501 60
  • Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction 60
  • Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 61
  • Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine 61
  • May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors 62
  • Appendix 63
  • Methodology 63
  • Coverage 63
  • Secondary Research 63
  • Primary Research 63
  • Expert Panel Validation 63
  • Contact Us 63
  • Disclaimer 64

List of Tables

  • Number of Products under Development for Nicotine Addiction, H2 2016 8
  • Number of Products under Development for Nicotine Addiction - Comparative Analysis, H2 2016 9
  • Number of Products under Development by Companies, H2 2016 10
  • Number of Products under Investigation by Universities/Institutes, H2 2016 11
  • Comparative Analysis by Clinical Stage Development, H2 2016 12
  • Comparative Analysis by Early Stage Development, H2 2016 13
  • Products under Development by Companies, H2 2016 14
  • Products under Investigation by Universities/Institutes, H2 2016 15
  • Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H2 2016 16
  • Nicotine Addiction - Pipeline by Astraea Therapeutics, LLC, H2 2016 17
  • Nicotine Addiction - Pipeline by Cerecor Inc., H2 2016 18
  • Nicotine Addiction - Pipeline by Chronos Therapeutics Limited, H2 2016 19
  • Nicotine Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H2 2016 20
  • Nicotine Addiction - Pipeline by Hager Biosciences, LLC, H2 2016 21
  • Nicotine Addiction - Pipeline by Heptares Therapeutics Limited, H2 2016 22
  • Nicotine Addiction - Pipeline by Omeros Corporation, H2 2016 23
  • Assessment by Monotherapy Products, H2 2016 24
  • Assessment by Combination Products, H2 2016 25
  • Number of Products by Stage and Target, H2 2016 27
  • Number of Products by Stage and Mechanism of Action, H2 2016 29
  • Number of Products by Stage and Route of Administration, H2 2016 30
  • Number of Products by Stage and Molecule Type, H2 2016 32
  • Nicotine Addiction - Dormant Projects, H2 2016 58
  • Nicotine Addiction - Discontinued Products, H2 2016 59

List of Figures

  • Number of Products under Development for Nicotine Addiction, H2 2016 8
  • Number of Products under Development for Nicotine Addiction - Comparative Analysis, H2 2016 9
  • Number of Products under Development by Companies, H2 2016 10
  • Comparative Analysis by Early Stage Products, H2 2016 13
  • Assessment by Monotherapy Products, H2 2016 24
  • Number of Products by Top 10 Targets, H2 2016 26
  • Number of Products by Stage and Top 10 Targets, H2 2016 26
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 28
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28
  • Number of Products by Stage and Routes of Administration, H2 2016 30
  • Number of Products by Molecule Types, H2 2016 31
  • Number of Products by Stage and Molecule Types, H2 2016 31
Back to Top